Skip to main content
GutCited

Curcumin therapy in inflammatory bowel disease: a pilot study.

Peter R Holt, Seymour Katz, Robert Kirshoff
Other Digestive diseases and sciences 2005 461 atıf
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'pmid\u003D16240238'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Çalışma Türü
Controlled Clinical Trial
Örneklem Büyüklüğü
10
Popülasyon
5 ulcerative proctitis and 5 Crohn's disease patients
Müdahale
Curcumin therapy in inflammatory bowel disease: a pilot study. Curcumin (pure preparation)
Karşılaştırıcı
None
Birincil Sonuç
Clinical improvement in UC proctitis and Crohn's
Etki Yönü
Positive
Yanlılık Riski
High

Abstract

Curcumin, a natural compound used as a food additive, has been shown to have anti-inflammatory and antioxidant properties in cell culture and animal studies. A pure curcumin preparation was administered in an open label study to five patients with ulcerative proctitis and five with Crohn's disease. All proctitis patients improved, with reductions in concomitant medications in four, and four of five Crohn's disease patients had lowered CDAI scores and sedimentation rates. This encouraging pilot study suggests the need for double-blind placebo-controlled follow-up studies.

Kısaca

All proctitis patients improved, with reductions in concomitant medications in four, and four of five Crohn's disease patients had lowered CDAI scores and sedimentation rates, which suggests the need for double-blind placebo-controlled follow-up studies.

Used In Evidence Reviews

Similar Papers